To include your compound in the COVID-19 Resource Center, submit it here.

Sick bay

Sick bay

MedImmune (MEDI) held up well last week after lowering its 2003 revenue guidance for FluMist. But investors already had come to

Read the full 227 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE